Phospholipase
Phospholipase is a member of a very complex group of enzymes that break down phospholipids into fatty acids and other compounds. Phospholipases are defined by the enzymatic reaction they catalyze. The classes are phospholipase A, which has members A1 and A2; phospholipase B, which can carry out the reactions of both A1 and A2; phospholipase C; and phospholipase D.
Phospholipase A2 (PLA2) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Phospholipase C (PLC) converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG and IP3 each control diverse cellular processes and are also substrates for synthesis of other important signaling molecules. PLC is thus central to many important interlocking regulatory networks. Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival.
Phospholipase Isoform Specific Products
All Product Categories
-
Phospholipase Related Products (336)
Related Products (336)
-
Antibodies (9)
-
Phospholipase Isoform Comparison
-
MJ33-OH
0 ImagesCat. No.: HY-129944CAS No.: 199106-13-3MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.
-
Lp-PLA2-IN-14
0 ImagesCat. No.: HY-153560CAS No.: 2756855-66-8Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like.
-
7-Hydroxycoumarinyl-γ-linolenate
0 ImagesCat. No.: HY-D1647CAS No.: 161180-12-77-Hydroxycoumarinyl-γ-linolenate is a cytosolic phospholipase A2 (cPLA2) fluorogenic substrate. 7-Hydroxycoumarinyl-γ-linolenate can be used to monitor the enzymatic activity of cPLA2.
-
Phospholipase A2, Porcine
0 ImagesCat. No.: HY-P3029CPhospholipase A2, Porcine (EC 3.1.1.4) hydrolyzes the β-ester bond of zwitterionic glycerophospholipids. Preferred substrates are phosphatidylcholine, phosphatidylethanolamine, and their plasmalogen analogues. Phosphatidylinositol and phosphatidylserine are also hydrolyzed. Phospholipase A2specifically recognizes the sn-2 acyl bond of phospholipids and catalytically hydrolyzes the bond releasing arachidonic acid and lysophospholipids.
-
U 84569
0 ImagesCat. No.: HY-182452CAS No.: 130736-25-3U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC50 value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation.
-
Brinazarone
0 ImagesCat. No.: HY-106611CAS No.: 89622-90-2Synonyms: SR 33287Brinazarone (SR 33287) is an inhibitor for acid lysosomal sphingomyelinase, and leads to cellular lipidosis. Brinazarone potentiates the cytotoxic effects of anti-Thy 1.2 AT15E RTA-IT on T2 cells and anti-CD5 T101 on CEM cells.
-
Melittin free acid
0 ImagesCat. No.: HY-P3906CAS No.: 123168-46-7Melittin free acid is a basic 26-amino-acid polypeptide, the major active ingredient of honeybee venom. Melittin free acid is an activator of phospholipase A2 (PLA2). Melittin free acid has broad-spectrum antifungal activity with MIC values of 0.4-60 μM. Melittin free acid hinders fungal growth by inducing cell apoptosis, repressing (1,3)-β-D-glucan synthase and participating in other pathways.
-
SB-435495 ditartrate
0 ImagesCat. No.: HY-19415BCAS No.: 304694-43-7SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM.
-
LY 178002
0 ImagesLY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
-
KARI 201
0 ImagesCat. No.: HY-171962CAS No.: 2376132-22-6KARI 201 is a selective, brain penetrant pand competitive acid sphingomyelinase (ASM) inhibitor with an IC50 of 338.3?nM. KARI 201 is a ghrelin receptor agonist. KARI 201 improves neuropathological features of Alzheimer's disease.
-
Me-Indoxam
0 ImagesCat. No.: HY-125157CAS No.: 172732-62-6Me-Indoxam is a potent and cell-impermeable secreted phospholipase A2 (sPLA2) inhibitor.
-
DS07551382
0 ImagesCat. No.: HY-177450CAS No.: 2488609-68-1DS07551382 is a potent phosphatidylserine synthase 1 (PTDSS1) inhibitor, thereby blocking intracellular phosphatidylserine synthesis. DS07551382 has antitumor activity.
-
cPLA2α-IN-derivative 1
0 ImagesCat. No.: HY-138871CAS No.: 1233706-89-2cPLA2α-IN-derivative 1 is an inactive alcohol derivative of a highly potent Cytosolic phospholipase A2α (cPLA2α) inhibitor.
-
A4333
0 ImagesCat. No.: HY-155343CAS No.: 3025827-56-6A4333 is biotinylated compound of A3373 (HY-155342) that inhibits Phospholipase D1 (PLD1), but not PLD2. A4333 plays an important role in antitumor activity.
-
SHP1-IN-2
0 ImagesCat. No.: HY-186140SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.
-
Avicin G
0 ImagesCat. No.: HY-134505CAS No.: 197787-17-0Avicin G is a sphingomyelinase inhibitor and plasma membrane disruptor. Avicin G inhibits the enzymatic activities of neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1), elevates intracellular sphingomyelin levels, and alters the distribution of sphingomyelin. Avicin G interferes with the lateral segregation of GTP- and GDP-bound H-Ras, inhibits the signal output of oncogenic K-Ras and H-Ras, reduces the phosphorylation of ERK and Akt, increases lysosomal pH, and inhibits the endocytic recycling of epidermal growth factor receptor. Avicin G can be used in research related to pancreatic ductal adenocarcinoma and non-small cell lung cancer.
-
Lp-PLA2-IN-16
0 ImagesCat. No.: HY-153561ACAS No.: 1865780-73-9Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc.
